home · filing · 0001193125-25-021345
8-K filed February 6, 2025, 6:59 PM ET
ticker MCRB
CIK 0001609809
leadership
confidence high
sentiment neutral
materiality 0.35
Seres Therapeutics appoints Hans-Juergen Woerle, M.D. to board, designated by Nestlé
Seres Therapeutics, Inc.
Board expanded to nine directors; Woerle appointed as Class III director effective Feb 4, 2025.
Woerle is Chief Medical Officer and Chief Scientific Officer at Nestlé Health Science since Nov 2018.
Designated by Nestlé under Securities Purchase Agreement requiring Nestlé to hold ≥10% of shares.
Initial option grant of 120k shares at $0.8056 strike, vesting over 4 years; annual retainer $45k plus $7.5k for committee service.
Woerle also serves on Enterome SA board and previously Cerecin Inc. board.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Effective 2025-02-04
Filed February 6, 2025, 6:59 PM ET
appointed Hans-Juergen Woerle, M.D., as a Class III director of the Company, effective immediately.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Hans-Juergen Woerle, M.D. was appointed as Class III director at Seres Therapeutics, Inc..
Action appointed
Role Class III director
Exact text from the filing
appointed Hans-Juergen Woerle, M.D., as a Class III director of the Company, effective immediately.
View on SEC.gov
Source: SEC EDGAR
accession 0001193125-25-021345
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.